3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
53
Neoplasms
36
Lung Neoplasms
25
Colorectal Neoplasms
23
Prostatic Neoplasms
17
Uterine Cervical Neoplasms
14
Motor Activity
13
Colonic Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Rectal Neoplasms
9
Anxiety Disorders
9
Urinary Bladder Neoplasms
8
Pancreatic Neoplasms
8
Obesity
8
Melanoma
8
Depression
8
Lymphoma
7
Hematologic Neoplasms
7
Endometrial Neoplasms
7
Vulvar Neoplasms
6
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Breast Carcinoma In Situ
6
Sarcoma
5
Pain
5
Hematopoietic and Lymphatic System Neoplasm
5
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Papillomavirus Infections
4
Neoplasm Metastasis
4
Interventions
padeliporfin
5
Nivolumab
3
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
anlotinib
2
alectinib
2
Vemurafenib
2
Sunitinib
2
Radiosurgery
2
Cyclophosphamide
2
Cisplatin
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
spartalizumab
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
lutetium Lu 177 dotatate
1
guadecitabine
1
genexol-PM
1
durvalumab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms by Site
×
Methods
×
Clear all
NCT03569605
2021-04-01
IMPACT
UNC Lineberger Comprehensive Cancer Center
Phase NA
Completed
280 enrolled